Eagle Pharmaceuticals Inc (EGRX) — Cash Flow Reinvestment Rate
Eagle Pharmaceuticals Inc (EGRX) has a Cash Flow Reinvestment Rate of 0.00x as of December 2022, reinvesting $19.00K (capex $10.00K plus investments $-9.00K) from operating cash flow of $37.56 Million. See EGRX free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Eagle Pharmaceuticals Inc Cash Flow Reinvestment Rate (2016–2022)
Historical reinvestment intensity for Eagle Pharmaceuticals Inc across 7 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Eagle Pharmaceuticals Inc.
Annual Cash Flow Reinvestment Rate for Eagle Pharmaceuticals Inc (2016–2022)
Year-by-year capital reinvestment analysis for Eagle Pharmaceuticals Inc. See EGRX free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 2.83x | $87.01 Million | $30.80 Million | $178.00K | ▲ +1312.1% |
| 2021 | 0.20x | $5.65 Million | $28.22 Million | $323.00K | ▼ -47.9% |
| 2020 | 0.38x | $18.99 Million | $49.50 Million | $747.00K | ▲ +1282.5% |
| 2019 | 0.03x | $1.55 Million | $55.99 Million | $777.00K | ▲ +446.6% |
| 2018 | 0.01x | $266.00K | $52.38 Million | $133.00K | ▼ -97.1% |
| 2017 | 0.18x | $10.37 Million | $58.92 Million | $5.19 Million | ▼ -85.9% |
| 2016 | 1.25x | $66.49 Million | $53.21 Million | $20.69 Million | — |